Reclaimed at end of life
Tonnes as filed. Totals combine re-used, recycled and safely disposed, because filers place comparable activity in different columns.
category_row_disappeared. FY 2025-26 omits ewaste, other, filed in this company's other years. Absence is not a reported zero.
reporting_boundary_changed. Reporting boundary changed across years: FY 2022-23 Standalone, FY 2023-24 Consolidated basis, FY 2024-25 Consolidated, FY 2025-26 Consolidated. Year-on-year figures cover different entities.
| Category | FY 2022-23 | FY 2023-24 | FY 2024-25 | FY 2025-26 |
|---|---|---|---|---|
| Plastics including packaging | not filed | not filed | 9,316.53 | 0 |
| E-waste | not filed | not filed | 0 | not filed |
| Hazardous waste | not filed | not filed | 335 | 0 |
| Other waste | 373 | not filed | not filed | not filed |
| Total reclaimed | 373 | 0 | 9,651.53 | 0 |
Recycled or reused input material
Share of total material by value, per material line as the company named it. Each line carries its own denominator, so they are never summed or averaged.
| Input material, as filed | FY 2022-23 | FY 2023-24 | FY 2024-25 | FY 2025-26 |
|---|---|---|---|---|
| The company, being in the business of pharmaceuticals, safety and quality of the products are of the highest priority since its products directly impact the health of end users. Therefore, the company does not reuse any material / chemical for manufacturing. The company is complying with EPR regulations through its plastic take back and recycle programs. | 0.0% | not filed | not filed | not filed |
NIC codes filed
Products and services accounting for 90 percent of turnover, latest filing.
| Code | Description as filed | Share of turnover |
|---|---|---|
| 2100 | Formulation (including Biologics) | 80.11% |
| 2100 | APIs | 2.11% |
| 10729 | Sweetener | 14.56% |
| 10509 | Nutritional drink | — |
| 10623 | Glucose powder | — |
| 10504 | Table spread | — |
| 20237 | Skincare products | — |
| 3250 | Medtech products | 2.88% |
Source filings
| Year | Basis | Taxonomy | Turnover as filed |
|---|---|---|---|
| FY 2022-23 | Standalone | 2021-09-30 | 84,21,21,03,610 |
| FY 2023-24 | Consolidated basis | 2024-04-30 | 1,03,17,60,00,000 |
| FY 2024-25 | Consolidated | 2025-05-31 | 1,45,90,10,00,000 |
| FY 2025-26 | Consolidated | 2026-02-28 | 1,10,76,40,00,000 |
Figures read from BRSR XBRL as filed. Nothing estimated or restated. How this works · Report an error